Illinois CancerCare

Recent papers from Illinois CancerCare

1. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4Journal of Clinical Oncology · 2026
2. Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (alliance)JNCI Cancer Spectrum · 2026
3. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialThe Lancet · 2026
4. Suspicion of cancer clinic: Community-Based diagnostic system- lung cancer cohort analysisHealthcare · 2026
5. Editorial: Exploring miRNA roles in neuroinflammation and brain aging: mechanisms and therapeutic potentialFrontiers in Immunology · 2026
6. Continuous or Fixed-Duration Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine · 2026
7. Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell CarcinomaClinical Cancer Research · 2026
8. Adolescents and Young Adults With Acute Lymphoblastic Leukemia: Qualitative Barriers and Facilitators to Guideline-Concordant CareCancer Control · 2026
9. A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).Journal of Clinical Oncology · 2026
10. A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).Journal of Clinical Oncology · 2026
11. Treatment decision-making after CAR-T and bispecific antibody therapy in relapsed/refractory multiple myeloma: Real-world perspectives from U.S. hematologist/oncologists.Journal of Clinical Oncology · 2026
12. The impact of adjusting for c-Kit exon 11 mutation status when comparing prognostic models for gastrointestinal stromal tumors for prediction of recurrence.Journal of Clinical Oncology · 2026
13. Tumor-specific drivers of PD-1/PD-L1 inhibitor brand preference in NSCLC, melanoma, and renal cell carcinoma: A U.S. oncologist perspective.Journal of Clinical Oncology · 2026
14. Organ preservation and local excision for rectal cancer: Long-term oncologic outcomes.Journal of Clinical Oncology · 2026
15. Lycopene and survival in patients with stage III colon cancer: Findings from CALGB (Alliance)/SWOG 80702.Journal of Clinical Oncology · 2026
16. Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.Journal of Clinical Oncology · 2026
17. Operational and clinical drivers of subcutaneous PD-1/PD-L1 inhibitor adoption: A mixed-methods analysis of U.S. oncology practice patterns.Journal of Clinical Oncology · 2026
18. An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices.Journal of Clinical Oncology · 2026
19. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1Journal of Clinical Oncology · 2026
20. Abstract 5038: Associations of WCRF/AICR recommendations with survival and chemotherapy outcomes in colon cancer: CALGB/SWOG 80702 (Alliance)Cancer Research · 2026